Mario Romeo | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Mario Romeo | Precision Medicine | Best Researcher Award

Dr. Mario Romeo, Dipartimento di Medicina di Precisione, Università degli Studi della Campania, LuigiVanvitelli, Italy

Dr. Mario Romeo is an accomplished medical doctor and researcher specializing in Digestive System Diseases. Graduating with top honors in Medicine and Surgery from the University of Campania “Luigi Vanvitelli” 🎓, he also earned a specialization in Gastroenterology and is pursuing a Ph.D. in Clinical and Experimental Medical Sciences. His research spans gut microbiota 🧫, liver disease 🏥, and metabolic dysfunction. A recipient of over 20 international awards 🏆, Dr. Romeo is widely recognized for his groundbreaking work in hepatology and gastroenterology. He actively contributes to scientific societies and fosters innovation in digestive health care.

Publication Profile 

Orcid

Education

Dr. Mario Romeo 🎓 began his academic journey with honors, earning his Diploma di Maturità Classica from Liceo Classico Gneo Nevio in June 2014 with a perfect score of 100/100 con lode 📜. He continued his excellence at the University of Campania “Luigi Vanvitelli,” completing his Laurea in Medicina e Chirurgia in July 2020 with 110/110 con lode 🩺, presenting a thesis on sarcopenia in compensated liver cirrhosis. He further specialized in Digestive System Diseases, earning his diploma in January 2025 with 50/50 con lode 🌟. His thesis explored RPR as a non-invasive tool in liver disease prediction.

Awards

Dr. Mario Romeo 🏅 has received numerous prestigious scholarships and awards in recognition of his excellence in hepatology and gastroenterology. Highlights include competitive fellowships like the AISF MasterClass 2022 🎓 and UEG Clinical Visiting Fellowship 2025 🌍. He has earned multiple travel grants ✈️ and best presentation prizes 🏆 at top events such as UEG Week, FISMAD, EASL, and ESCI for groundbreaking research on liver diseases, MAFLD, gut microbiota, and non-invasive biomarkers. His multidisciplinary “CoCoNut” protocol 🍏 also gained international acclaim. These accolades affirm his dynamic role in advancing liver research and patient care through innovation and collaboration.

Research Focus 

Dr. Mario Romeo’s research focus lies predominantly in Hepatology and Gastroenterology, with a strong emphasis on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), liver cirrhosis, and gut-liver axis dynamics 🧬🍽️. His work explores non-invasive biomarkers, body composition, oxidative stress, and gut microbiota 🧫, highlighting their roles in disease progression and clinical outcomes. He also investigates multidisciplinary management strategies combining nutritional, psychological, and pharmacological interventions 🥗🧠💊. Dr. Romeo contributes significantly to understanding liver-related complications like sarcopenia, dysgeusia, and hepatocellular carcinoma 🎯. His innovative, patient-centered research enhances predictive diagnostics and therapeutic approaches in chronic liver diseases.

Publication Top Notes

  • Spleen Area Affects the Performance of the Platelet Count–Based Non-invasive Tools in Predicting First Hepatic Decompensation in Metabolic Dysfunction–Associated Steatotic Liver Disease Cirrhosis
  • Nutritional and Psychological Support as a Multidisciplinary Coordinated Approach in the Management of Chronic Liver Disease: A Scoping Review
  • Letter: Different Risk of Acute Variceal Bleeding According to the Liver Disease Aetiology in Decompensated Cirrhosis Patients Receiving Carvedilol‐Based Primary Prophylaxis—May Insulin Resistance Unloose This Gordian Knot?
  • Exploring the Classic and Novel Pathogenetic Insights of Plastic Exposure in the Genesis and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • The Role of the Gut–Biliary–Liver Axis in Primary Hepatobiliary Liver Cancers: From Molecular Insights to Clinical Applications
  • Primary biliary cholangitis, Celiac Disease, and MASLD: the triumvirate of steatosis. How should we manage this triple overlap?
  • Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)?
  • FLAME: Training and Validating a Newly Conceived Model Incorporating Alpha-Glutathione-S-Transferase Serum Levels for Predicting Advanced Hepatic Fibrosis and Acute Cardiovascular Events in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • Dysgeusia in MASLD-related advanced chronic liver disease (ACLD): a silent driver towards the “Bermuda” triangle of malnutrition-sarcopenia-frailty severely affecting prognosis
  • Vanek’s Tumour as a Rare Cause of Dyspeptic Syndrome in a Patient with Primary Biliary Cholangitis: A Case Report
  • Systemic Oxidative Stress Correlates with Sarcopenia and Pruritus Severity in Primary Biliary Cholangitis (PBC): Two Independent Relationships Simultaneously Impacting the Quality of Life—Is the Low Absorption of Cholestasis-Promoted Vitamin D a Puzzle Piece?
  • Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study

Salma Khan | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Salma Khan | Precision Medicine | Best Researcher Award

Assoc. Prof. Dr. Salma Khan, Loma Linda University, United States

Assoc. Prof. Dr. Salma Khan is a distinguished physician-scientist specializing in gynecologic oncology and thyroid cancer research. With a Ph.D. from Kumamoto University 🇯🇵 and faculty appointments at Loma Linda University 🏥, she excels in translational cancer biology. Her groundbreaking work on health disparities, molecular oncology, and thyroid cancer genomics has earned her multiple honors, including the 2024 AACR Women Cancer Research Award 🌟. She actively contributes to the American Thyroid Association, NIH peer review panels, and serves on several journal editorial boards 📚. Dr. Khan is also a dedicated mentor and advocate for diversity in science and medicine .

Publication Profile

Google Scholar

Education

Assoc. Prof. Dr. Salma Khan began her academic journey with a Higher Secondary Certificate from Govt. M.M. Ali College, Tangail, Bangladesh (1983–1985). 🎓 She earned her MBBS from Gandhi Medical College, Bhopal, India (1986–1991), followed by an internship at Hamidia Hospital (1991–1992). 🏥 Dr. Khan completed her residency in Obstetrics and Gynecology at IPGMR, Dhaka (1992–1994), and pursued a fellowship at Kumamoto University School of Medicine, Japan (1995–1996). 🌸 Her academic excellence culminated in a Ph.D. in Gynecologic Oncology from Kumamoto University (1996–2000), showcasing her dedication to advancing women’s health.

Awards

Assoc. Prof. Dr. Salma Khan has received numerous accolades throughout her distinguished career. She was honored with the Best Mentor Award by BMANA in 2025 (San Francisco), 2023 (Los Angeles), and 2020 (Dallas). 🌟 In 2024, she received the AACR Women Cancer Research Award and the Best Basic Science Research Award in California. 🎗️ A frequent recipient of Travel Awards from the American Thyroid Association (2016–2023), Dr. Khan also earned top honors at scientific meetings and was a keynote speaker in Japan and Korea (2015). 🌍 Her journey began with prestigious academic scholarships in Bangladesh, India, and Japan.

Research Focus

Assoc. Prof. Dr. Salma Khan focuses her research on cancer biology, with a specialized emphasis on exosomes, survivin biology, and biomarkers for early cancer detection, particularly in prostate and breast cancers. Her groundbreaking studies explore how tumor-derived exosomes contribute to cell signaling, apoptosis inhibition, and metastasis, highlighting survivin as a pivotal player and potential diagnostic marker. Dr. Khan’s work intersects molecular oncology and translational medicine, aiming to bridge lab findings with clinical applications. Her contributions are instrumental in advancing non-invasive diagnostic tools and improving cancer prognosis across diverse populations.

Publication Top Notes

Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer

Survivin is released from cancer cells via exosomes

Early diagnostic value of survivin and its alternative splice variants in breast cancer

Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential

PTEN promoter is methylated in a proportion of invasive breast cancers

Human villous macrophage-conditioned media enhance human trophoblast growth and differentiation in vitro

Differential MicroRNA‐Signatures in Thyroid Cancer SubtypesProteomic profiling of serum-derived exosomes from ethnically diverse prostate cancer patients

Exosomes secreted from human cancer cell lines contain inhibitors of apoptosis (IAP)

LATS1 phosphorylates forkhead L2 and regulates its transcriptional activity

The emerging role of exosomes in survivin secretion

Curcumin induces pancreatic adenocarcinoma cell death via reduction of the inhibitors of apoptosis

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Dr. Nigatu Gebrehiwot, Zhengzhou University, China

Dr. Nigatu Gebrehiwot is a dedicated PhD candidate in Pharmacology at Zhengzhou University, China, specializing in drug safety evaluation. He holds a Master’s in Clinical and Administrative Pharmacy from Xi’an Jiaotong University and a Bachelor of Pharmacy from Mekelle University, where he was recognized as an outstanding student. A published researcher and global presenter, Dr. Gebrehiwot has earned accolades including recognition at ISPOR in Barcelona. He is actively involved in multiple international scientific societies and brings strong expertise in pharmacotherapy, academic writing, and collaborative healthcare research. His work explores methionine metabolism and innovative therapeutic strategies.

Publication Profile

Orcid

Education

Dr. Nigatu Gebrehiwot holds a Master’s degree in Clinical and Administrative Pharmacy from Xi’an Jiaotong University, where his research earned an award at the 21st European Congress ISPOR Health Outcome Research Conference in Barcelona, Spain. 🏅 He also earned a Bachelor’s degree in Pharmacy from Mekelle University, where he was recognized as the most outstanding student in his class. 🎓 His academic achievements reflect his dedication to advancing the field of pharmacy, blending clinical expertise with research excellence. Dr. Gebrehiwot’s work continues to impact the healthcare landscape positively.

Experience

Dr. Nigatu Gebrehiwot is currently a Ph.D. candidate in Pharmacology at the Center for Drug Safety Evaluation and Research, Zhengzhou University, Henan, China, since September 2022. 🎓 Prior to this, he served as the Principal Scientific Officer at the Federal Ministry of Health (FMOH) in Ethiopia from June 2020 to 2021. During his tenure, Dr. Gebrehiwot managed national disease programs and medicines, overseeing the funding and evaluation of treatment guidelines and drug therapy protocols in accordance with Ethiopian legislation and EFDA guidelines. 💊 He also led technical committees focused on antimicrobial therapy, cancer, and chronic disease management.

Awards

Dr. Nigatu Gebrehiwot received a prestigious award for his research abstract at the 21st European Congress ISPOR Health Outcome Research conference in Barcelona, Spain. 🏆 This recognition underscores the significant impact of his work in the field of pharmacology and health outcome research. 🌍 His contributions continue to advance knowledge and influence healthcare practices, making him a respected figure in his field. 💡 Dr. Gebrehiwot’s dedication to research excellence and his ability to address critical health issues have earned him well-deserved acknowledgment on an international stage.

Research Focus

Dr. Nigatu Tadesse’s research primarily focuses on molecular alterations in disease processes, with an emphasis on metabolic pathways and their potential as diagnostic and therapeutic targets. His work on gastric intestinal metaplasia and methionine metabolism sheds light on novel approaches to diagnosis and treatment. Additionally, Dr. Tadesse has contributed significantly to pharmacology, particularly the study of traditional medicines like Dioscorea zingiberensis, investigating its phytochemistry, clinical applications, and toxicity. His research also extends to industrial processes, such as wastewater treatment in diosgenin production. His interdisciplinary work connects biomedicine, pharmacology, and environmental science.

Publication Top Notes

Molecular Alterations in Gastric Intestinal Metaplasia Shed Light on Alteration of Methionine Metabolism: Insight into New Diagnostic and Treatment Approaches

Knowledge, attitude and antibiotic prescribing patterns of medical doctors providing free healthcare in the outpatient departments of public hospitals in Sierra Leone: A national cross-sectional study

Dioscorea zingiberensis C. H. Wright: An overview on its traditional use, phytochemistry, pharmacology, clinical applications, quality control, and toxicity

First total synthesis of a novel amide alkaloid derived from Aconitum taipeicum and its anticancer activity

Methods to treat the industrial wastewater in diosgenin enterprises produced from Diosorea zingiberensis C. H. Wright

Safety investigation on total steroid saponins extracts from Dioscorea zingiberensis C.H. Wright: Sub-acute and chronic toxicity studies on dogs

Zhi-Ming Shao | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Zhi-Ming Shao | Precision Medicine | Best Researcher Award

Prof. Zhi-Ming Shao, Fudan University Shanghai Cancer Center, China

Prof. Zhi-Ming Shao is a distinguished surgical oncologist and global leader in breast cancer research. A graduate of Shanghai Medical University, he chairs the Department of Breast Surgery at Fudan University Shanghai Cancer Center and directs its Breast Cancer Institute. With extensive postdoctoral experience in the U.S. and over 30 years of academic excellence, Prof. Shao has received numerous national honors, including the Chang Jiang Scholar and China’s Most Beautiful Doctor Award. His groundbreaking research, published in top journals like Nature Genetics and Cancer Cell, has significantly advanced precision oncology and breast cancer therapy worldwide.

Publication Profile

Scopus

Education

Prof. Zhi-Ming Shao began his medical journey at Shanghai Medical University, where he earned his Bachelor of Medicine (1980–1985). Driven by a passion for cancer treatment, he pursued a Residency in Surgical Oncology (1985–1990) at the prestigious Fudan University Shanghai Cancer Center. During this period, he also completed his Doctor of Medicine (M.D.) through a Postgraduate Course in Surgical Oncology (1987–1990) at Shanghai Medical University. His comprehensive education laid a strong foundation for his distinguished career in oncology, combining clinical expertise with academic excellence.

Experience

Prof. Zhi-Ming Shao has undergone extensive professional training and leadership roles in oncology. He began as a Postdoctoral Research Fellow (1990–1991) at Wake Forest University, followed by a role as Research Associate (1991–1995) at the University of Maryland Cancer Center. Returning to China, he became Associate Professor (1996–1998) and then Professor (1998–present) at Fudan University Shanghai Cancer Center. Since 2000, he has chaired the Department of Breast Surgery and became Director of the Breast Cancer Institute (2019–present). He also served as Chairman of the 8th Asian Breast Cancer Association (2010–2012) and is now Honorary Chairman of the China Anti-Cancer Association.

Awards

Prof. Zhi-Ming Shao has received numerous prestigious honors and awards throughout his career. In 1998, he was named one of the first batch of distinguished professors of the Chang Jiang Scholars Program. He was awarded the National Science Fund for Distinguished Young Scholars in 2001 and recognized as a Young and Middle-aged Expert with Outstanding Contributions by the Ministry of Health of China in 2004. His accomplishments include the National Prize of Science and Technology Progress (Grade II) in 2005, the National May Day Labor Medal in 2008, and the Chinese Physician Prize in 2020. He was also honored with the 2023 China’s Most Beautiful Doctor Award.

Research Focus

Prof. Zhi-Ming Shao’s research focuses on breast cancer, particularly in the areas of pathogenesis and treatment strategies. His work explores novel therapeutic approaches, such as targeting specific pathways involved in triple-negative breast cancer (TNBC) and HER2-positive breast cancer, as well as developing targeted imaging agents for improved diagnosis. Prof. Shao has contributed significantly to understanding the molecular mechanisms of breast cancer progression and therapy resistance. His studies involve investigating genetic markers, tumor microenvironment interactions, and new treatment combinations. Overall, his research aims to improve clinical outcomes for breast cancer patients, especially in advanced or resistant cases.

Publication Top Notes

Breast cancer: pathogenesis and treatments

Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4

LINC01235 Promotes Clonal Evolution through DNA Replication Licensing-Induced Chromosomal Instability in Breast Cancer

Pilot Study of Nectin-4–Targeted PET Imaging Agent 68Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human

Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial

The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer

O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-β signaling to breast cancer progression

Symptoms Related to Brachial Plexus Neuropathy After Supraclavicular Irradiation and Boost in Breast Cancer

Prognostic value of metabolic signature on 18F-FDGuptake in breast cancer patients after radiotherapy

TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer

Pilar Hernandez Jimenez | Personalized Medicine | Women Researcher Award

Published on by Top Pharmaceutical

Pilar Hernandez Jimenez | Personalized Medicine | Women Researcher Award

Dr. Pilar Hernandez Jimenez, Hospital Universitario 12 de Octubre, Spain

Dr. María del Pilar Hernández Jiménez 🩺🔬 is a specialist in internal medicine with a focus on infectious diseases. She earned her M.D. from the Universidad de Alcalá (2011) and completed her MIR in Internal Medicine at HU 12 de Octubre (2013-2018). With expertise in HIV, tropical diseases, and antimicrobial resistance, she has contributed to multiple research projects, publishing 21 indexed articles (h-index 9). Currently, she is a Río Hortega researcher at Instituto de Salud Carlos III and a consultant at HU 12 de Octubre. Her doctoral thesis (2024) explores multidrug-resistant Pseudomonas aeruginosa.

Publication Profile

orcid

Education

Dr. Pilar Hernandez Jimenez 🎓 earned her Ph.D. in Health Sciences (2024) from Universidad Complutense de Madrid. She holds a Master’s in Infectious Diseases in Immunocompromised Patients 🦠 and has pursued multiple postgraduate specializations in infectious diseases, tropical medicine 🌍, and HIV 🏥. Her expertise spans critical areas of global health, focusing on combating infectious diseases and improving patient outcomes. With a strong academic foundation and extensive clinical knowledge, Dr. Hernandez Jimenez is dedicated to advancing research and medical practices in infectious disease management, contributing significantly to the field of immunocompromised patient care.

Experience

Dr. Pilar Hernandez Jimenez 🏥 currently serves at Instituto de Salud Carlos III and Hospital Universitario 12 de Octubre, where she plays a vital role in infectious disease research and hospital consultations. With extensive experience in leading studies on infectious diseases 🦠, she has contributed significantly to COVID-19 research 🦠, HIV studies 🏳️‍🌈, and infection management in immunocompromised patients 🤝. Her work bridges clinical practice and research, enhancing patient care and public health strategies. Through collaboration with top medical institutions, Dr. Hernandez Jimenez continues to make a meaningful impact on global health and infectious disease management.

International Exposure

Dr. Pilar Hernandez Jimenez 🌍 has gained extensive international exposure through Erasmus and MIR training in Spain 🇪🇸 and France 🇫🇷, enriching her expertise in infectious diseases. Her global collaborations extend to Brazil 🇧🇷, where she conducted research at Fundação de Medicina Tropical Doutor Heitor Vieira Dourado 🦠, contributing to advancements in tropical medicine and infectious disease management. These international experiences have allowed her to engage with diverse healthcare systems, collaborate with leading researchers, and enhance her medical practice on a global scale. Dr. Hernandez Jimenez continues to foster cross-border medical innovation and research excellence.

Research Focus

Dr. María del Pilar Hernández-Jiménez is a distinguished infectious disease researcher 🦠 specializing in prosthetic joint infections, multidrug-resistant bacteria, and antimicrobial treatments 💊. Her research focuses on periprosthetic infections, Pseudomonas aeruginosa, carbapenemase-producing Klebsiella pneumoniae, and infections in immunocompromised and transplant patients 🏥. She has contributed significantly to clinical microbiology, antimicrobial resistance, and infection control 📊. Dr. Hernández-Jiménez’s work extends to COVID-19-related infections and innovative treatments for latent tuberculosis in transplant recipients 🌍. Her extensive collaborations and impactful publications highlight her global influence in infectious disease research 🔬.

Publication Top Notes

Periprosthetic Infection of Transfibular Ankle Arthroplasties Managed with Implant Retention: Anatomical Limitations of Surgical Debridement

Appropriate Duration of Antimicrobial Treatment for Prosthetic Joint Infections: A Narrative Review

Production of OXA-48 carbapenemase acts as an independent risk factor for poor outcome in Klebsiella pneumoniae infection

Enhancing screening adherence for strongyloides infection in latinx inpatients with COVID-19: a local protocol implementation study.

Henryk Mazurek | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Henryk Mazurek | Precision Medicine | Best Researcher Award

Prof. Henryk Mazurek, National Tuberculosis and Lung Diseases Institute, Department of Pneumonology and Cystic Fibrosis, Poland

Prof. Henryk Mazurek is a distinguished pulmonologist, allergologist, and pediatrician specializing in pediatric pulmonology and respiratory diseases. He serves as the Head of the Department of Pneumonology and Cystic Fibrosis at the National Tuberculosis and Lung Diseases Institute, Poland 🇵🇱. With over 60 original research articles and extensive contributions to medical literature 📚, he has significantly advanced the understanding of chronic respiratory diseases, asthma, and cystic fibrosis. A member of esteemed scientific societies 🌍, he actively collaborates internationally and leads impactful research projects. His work in AI-assisted diagnostics and pulmonary care is shaping the future of respiratory medicine. 🚀

Publication Profile

Scopus

Professional Background

Professor Henryk Mazurek is a distinguished pulmonary disease specialist, allergologist, pediatrician, and pediatric pulmonology expert 🩺. He completed postgraduate studies in respiratory pathophysiology in France 🇫🇷 and holds the title of Full Professor in medical and health sciences 🎓. As an academic, he teaches nursing and postgraduate medical training in pediatrics, allergology, and lung diseases. He has authored and co-authored over 60 original articles, 100+ textbook chapters, and numerous scientific publications 📚. A sought-after lecturer, he shares his expertise at medical conferences, educating physicians and healthcare professionals worldwide 🌍.

Memberships

Prof. Henryk Mazurek is an esteemed member of several prestigious scientific organizations, fostering international collaboration in respiratory medicine 🌍🫁. He holds a combined membership in the European Respiratory Society (ERS) / Polish Respiratory Society, along with memberships in the Polish Society of Allergology and the Polish Society of Pediatric Pulmonology, where he is an honorary member 🎖️. For many years, he contributed to the Scientific Council of the Institute of Tuberculosis and Lung Diseases in Warsaw 🏥. Additionally, he served on the Main Boards of the Polish Society of Allergology (2015-2021) and the Polish Society of Cystic Fibrosis (2014-2018) 📚.

Industry Projects

Prof. Henryk Mazurek has actively contributed to over 50 industry-sponsored clinical trials, showcasing his expertise in applied research 🔬. His consultancy work plays a crucial role in bridging academic research with real-world healthcare applications, particularly in advancing treatment strategies for cystic fibrosis 🫁. Through his collaborations with pharmaceutical and medical device companies 💊🩺, he has successfully translated research findings into clinical practice, improving patient outcomes. His dedication to innovation and evidence-based solutions continues to shape the future of respiratory medicine, reinforcing his impact on both academia and industry. 🌍

Research Focus

Prof. Henryk Mazurek’s research primarily focuses on respiratory diseases 🫁, particularly in cystic fibrosis 🧬, pediatric pulmonology 👶, and ventilator-associated pneumonia 🏥. His work explores innovative AI-facilitated home monitoring 🤖 for cystic fibrosis, childhood asthma treatments 🌬️, and the effects of medications like Gabapentin on post-operative pain 💊. He has also studied risk factors for pneumonia 🦠 and strategies for its prevention in ventilated patients. His expertise lies in pulmonary infections, inflammatory biomarkers, and personalized medicine 🧑‍⚕️. His contributions significantly impact respiratory healthcare, enhancing diagnostic and therapeutic approaches for both pediatric and adult patients.

Publication Top Notes

AI-facilitated home monitoring for cystic fibrosis exacerbations across pediatric and adult populations

Childhood asthma treatment based on indirect hyperresponsiveness test: Randomized controlled trial

The Effects of Gabapentin on Post-Operative Pain and Anxiety, Morphine Consumption and Patient Satisfaction in Paediatric Patients Following the Ravitch Procedure—A Randomised, Double-Blind, Placebo-Controlled, Phase 4 Trial

Risk Factors and Protective Factors against Ventilator-Associated Pneumonia—A Single-Center Mixed Prospective and Retrospective Cohort Study

Automatic continuous control of cuff pressure and subglottic secretion suction used together to prevent pneumonia in ventilated patients—a retrospective and prospective cohort study

Chronic bacterial pulmonary infections in advanced cystic fibrosis differently affect the level of sputum neutrophil elastase, IL-8 and IL-6

Edwin Posadas | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Edwin Posadas | Precision Medicine | Best Researcher Award

Dr. Edwin Posadas, Cedars-Sinai Cancer, United States

Dr. Edwin M. Posadas is a distinguished oncologist and urologist specializing in prostate cancer research and treatment. He is a Professor at Cedars-Sinai Medical Center and UCLA, co-Director of the Cancer Therapeutics Program, and Medical Director of the Urologic Oncology Program. A Johns Hopkins graduate, he trained at the NIH and University of Michigan. Dr. Posadas has earned numerous accolades, including Castle Connolly Top Doctor and Sigma Xi Honors. An active researcher, mentor, and leader in oncology, he contributes to multiple scientific committees and journals, shaping the future of cancer care. 📚🔬✨

Publication Profile

orcid

Education

Dr. Edwin Posadas 🎓 began his academic journey at Johns Hopkins University, earning dual B.E.S. degrees in Biomedical and Chemical Engineering (1993) with summa cum laude honors. His studies focused on biological transport systems and physiological fluid mechanics. He then pursued his M.D. at Johns Hopkins School of Medicine (1998) 🩺, followed by an internship and residency at the University of Michigan Medical Center (2001) 🏥. Further specializing, he completed a fellowship in Medical Oncology and Hematology (2005) 🧬 at the National Cancer Institute & National Heart, Lung, and Blood Institute, solidifying his expertise in cancer research and treatment. 🔬💙

Professional Associations

Dr. Edwin Posadas 🩺 is an esteemed member of numerous professional associations and scholarly societies, reflecting his dedication to oncology, urology, and medical ethics. He joined the American Medical Association (1993) 🏥, Association of Philippine Physicians of America (1998) 🇵🇭, and American College of Physicians (1998) 🩻, later becoming a Fellow (2010) 🎖️. His contributions extend to the American Society of Clinical Oncology (2001) 🧬, American Association for Cancer Research (2001) 🔬, and European Society of Medical Oncology (2012) 🌍. He also actively participates in cancer research initiatives, including the Cancer Moonshot Program (2016) 🚀 and the Medical Oncology Association of Southern California (2022) 🌿.

Achievements

Dr. Edwin Posadas 🩺 has built a distinguished career in internal medicine and medical oncology, dedicated to advancing patient care and cancer research. In 2001, he became certified in Internal Medicine 🏥, laying the foundation for his expertise in diagnosing and managing complex diseases. His passion for oncology led him to further specialize, earning his Medical Oncology certification in 2019 🧬🎗️. With decades of experience, he remains committed to innovative cancer treatments, translational research, and personalized patient care, making significant contributions to the oncology community through clinical practice, research, and professional collaborations. 🔬💙

Research Focus

Dr. Edwin M. Posadas is a distinguished researcher specializing in prostate cancer 🔬, metastasis 🧬, and nanotechnology-based diagnostics 🏥. His work focuses on understanding the molecular determinants of metastasis in prostate cancer, particularly liver and visceral metastases. He has contributed to the development of nanotechnology solutions for early cancer detection 🩸 and circulating tumor cell profiling. His research also explores the role of FYN kinase in cancer growth and motility. With multiple grants from the National Cancer Institute and Congressionally Directed Medical Research Programs, his pioneering work is advancing precision oncology and metastasis prevention in prostate cancer patients. 🎗️

Publication Top Notes

Determinants of Liver Metastasis

A Nanotechnology Solution for Early Detection of Micrometastatic Prostate Cancer After Radical Prostatectomy

A blood test to identify prostate cancer patients at risk for visceral metastasis

Thermoresponsive NanoVelcro CTC Purification System for Prostate Cancer Profiling

FYN Is a Key Regulator of Metastasis in Prostate Cancer

Targeting FYN in Prostate Cancer: A Key Regulator of Growth and Motility

KYU SHIK MUN | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

KYU SHIK MUN | Personalized Medicine | Best Researcher Award

Assist. Prof. Dr. KYU SHIK MUN, Cedars-Sinai Medical Center, United States

Assist. Prof. Dr. Kyu Shik Mun is a distinguished researcher in cystic fibrosis (CF) and biomedical engineering 🧬. As a Principal Investigator and Co-Director, he has led groundbreaking projects on CF-related diabetes, organ-on-a-chip models, and personalized CF therapy 🏥. His work, funded by organizations like the Cystic Fibrosis Foundation and Vertex Pharmaceuticals, has yielded significant patents and high-impact publications 📑. With 733 citations, an h-index of 10, and an i10-index of 10, Dr. Mun continues to drive innovations in CF research, bridging biomedical science and translational medicine 🔬.

Publication Profile

Google Scholar

Professional Background

Assist. Prof. Dr. Kyu Shik Mun earned his Ph.D. in the Materials Science and Engineering Program at the University of Cincinnati 🎓. In 2016, he joined the Cystic Fibrosis Research Center at Cincinnati Children’s Hospital, where he pioneered a microfluidic-based organ-on-chip program from scratch 🏥🧬. His groundbreaking research focused on studying cystic fibrosis and related disorders. In 2021, he was promoted to Assistant Professor at Cedars-Sinai 🏆, where he continues to advance in vitro cell culture models using organ-on-chip technology and 3D bioprinting 🖨️🔬, contributing to innovative solutions in biomedical research and personalized medicine.

Awards

Assist. Prof. Dr. Kyu Shik Mun has received numerous prestigious honors and awards throughout his academic and professional journey 🎖️. He was awarded multiple Outstanding Grade Scholarships at Gangneung National University 🏅 (2000–2009) and recognized for excellence with department and presidential awards 🏆. His achievements include a scholarship from the Korean Broadcasting System 📺 and the Korea Research Foundation 🌏. During his Ph.D. at the University of Cincinnati, he earned a University Graduate Scholarship 🎓 (2010–2014). His research has been recognized by the American Gastroenterological Association and the Cystic Fibrosis Foundation 🧬, receiving multiple Best Abstract and Early Career Investigator awards (2017–2024) 🥇.

Experience 

Assist. Prof. Dr. Kyu Shik Mun has been actively involved in non-clinical teaching, contributing to journal clubs and lab mentoring 📚🎤. He has delivered key presentations on organ-on-a-chip technology 🧬, including talks at Cincinnati Children’s Hospital (2020) and Cedars-Sinai (2021) 🏥. His mentorship spans postdoctoral fellows, research associates, and Ph.D. students, guiding projects in 3D bioprinting 🖨️ and patient-derived lung-on-a-chip models 🌬️. Since 2016, he has mentored 15 summer and rotation students—including high school, college, Ph.D., and MD candidates—on fabricating organ-on-a-chips and culturing cells, fostering the next generation of biomedical researchers 🔬.

Research Focus

Assist. Prof. Dr. Kyu Shik Mun’s research primarily focuses on nanotechnology 🧪, biosensors 🧫, and biomedical engineering 🏥. His work spans optical interferometric biosensors for label-free detection, organ-on-a-chip models for diseases like cystic fibrosis 🫁, and TiO₂ nanotube arrays for applications in solar cells ☀️ and photocatalysis. He also explores drug discovery 💊 by targeting molecular pathways in cystic fibrosis and related disorders. His interdisciplinary research integrates materials science 🏗️, biophysics ⚛️, and microfluidics 🔬 to develop innovative medical technologies, aiming to advance precision medicine 🎯 and renewable energy solutions 🌱.

Publication Top Notes

A Stable, Label-free Optical Interferometric Biosensor Based on TiO2 Nanotube Arrays

Patient-derived pancreas-on-a-chip to model cystic fibrosis-related disorders

Guided construction of single cell reference for human and mouse lung

Targeting the pregnane X receptor using microbial metabolite mimicry

Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations

Surface passivation of highly ordered TiO2 nanotube arrays and application to dye-sensitized solar cells using the concept of isoelectric point

Targeting DNAJB9, a novel ER luminal co-chaperone, to rescue ΔF508-CFTR

Guanylate cyclase 2C agonism corrects CFTR mutants

Cystic Fibrosis Human Organs-on-a-Chip

Johan Alexander Villada Ramos | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Johan Alexander Villada Ramos | Drug Discovery and Development | Best Researcher Award

Prof. Johan Alexander Villada Ramos, Universidad del Quindío, Colombia

Johan Alexander Villada Ramos is a Ph.D. candidate in Sciences at Universidad del Quindío, specializing in natural alternatives to synthetic pesticides 🌱🦠. He holds a Master’s in Biomedical Sciences, earning a meritorious distinction 🏅, and a Biology degree. His research spans bioactive plant compounds, cancer prevention, and lipid metabolism. As a university lecturer 📚, he teaches molecular biology and biochemistry. With multiple research projects, publications, and awards, including the Carlos Corredor Pereira National Award in Biomedical Sciences (2024) 🏆, Johan is a dedicated scientist pushing the boundaries of biotechnology and microbiology.

Publication Profile

Orcid

Education

Prof. Johan Alexander Villada Ramos 🎓 is a doctoral student in Sciences at the Universidad del Quindío, focusing on the bioactivity of free and microencapsulated Tagetes erecta L. 🌿 as an alternative to synthetic pesticides against the avocado weevil Heilipus lauri 🥑. He earned a Master’s in Biomedical Sciences (2018–2022) with meritorious distinction 🏅, researching the effects of Passiflora edulis extract on lipid metabolism enzymes in human colorectal adenocarcinoma cells. His Biology degree (2013–2018) involved evaluating the antibacterial activity of Tagetes patula L. against Ralstonia solanacearum. Additionally, he trained in microbiology and biotechnology lab preparation at SENA (2017–2018) 🔬.

Professional Achievements

Prof. Johan Alexander Villada Ramos 🎓 has made significant contributions to biomedical and biological research. He earned a meritorious distinction 🏅 for his master’s research on Passiflora edulis 🍊 and its effects on lipid metabolism in colorectal cancer cells. Holding a Biology degree 🔬, his studies focused on the antimicrobial activity of plant extracts against pathogens. He has been actively involved in high-impact research projects 📚 at prestigious institutions, including Pontificia Universidad Javeriana and Universidad del Quindío. His work continues to advance natural alternatives 🌱 in disease management, reinforcing his dedication to scientific discovery and innovation.

Leadership in Academia

Prof. Johan Alexander Villada Ramos 🎓 is a dedicated academic leader, serving as a lecturer 📖 in molecular biology, biochemistry, and microbiology 🔬 at Universidad del Quindío. Passionate about education, he actively contributes to curriculum development 🏫, ensuring that students receive up-to-date and high-quality training. Additionally, he plays a key role in laboratory training 🧪, equipping future scientists with essential research skills. His commitment to fostering scientific knowledge and practical expertise strengthens the university’s academic foundation, inspiring students to excel in the fields of biotechnology, microbiology, and biomedical sciences. 🚀

Research Focus

Prof. Johan Alexander Villada Ramos specializes in natural product chemistry, biochemistry, and phytopharmacology, with a strong focus on the antioxidant, antibacterial, and anticancer properties of plant extracts. His research explores bioactive compounds from medicinal plants, such as Coffea arabica ☕, Passiflora edulis 🍃, and Tagetes patula 🌼, investigating their effects on oxidative stress, protein oxidation, and bacterial inhibition 🦠. His studies contribute to pharmaceutical development, food science, and biomedicine, aiming to harness plant-derived compounds for disease prevention and therapeutic applications. 🏥

Publication Top Notes

Potencial antioxidante del extracto de hoja de Coffea arabica sobre la lipoperoxidación y oxidación proteica en un modelo de músculo bovino

Identification of potential bioactive compounds of Passiflora edulis leaf extract against colon adenocarcinoma cells

Evaluation of antibacterial activity of extract and essential oil of Tagetes patula L. in vitro against Ralstonia solanacearum biovar 2

Ndzembanteh Aboubakary Nulambeh | Pharmacogenomics | Best Researcher Award

Published on by Top Pharmaceutical

Ndzembanteh Aboubakary Nulambeh | Pharmacogenomics | Best Researcher Award

Dr Ndzembanteh Aboubakary Nulambeh, The University of Bamenda, Cameroon

Dr. Ndzembanteh Aboubakary Nulambeh 🇨🇲 is a seasoned economist with over eight years of experience in academia and research. He holds a PhD in International Economics from Bursa Uludag University, Turkey, and an MSc in Economics from the International Islamic University of Malaysia. Currently, he serves as an Assistant Lecturer at the Higher Institute of Management Studies and ISTGAC Maaron University Institute in Cameroon. His expertise includes macro & microeconometrics, sustainable finance, and Islamic economics. With multiple publications in high-impact journals, he actively researches green growth, climate neutrality, and financial development. Dr. Ndzembanteh is fluent in English and proficient in French.

Publication Profile

orcid

Educational Background

Dr. Ndzembanteh Aboubakary Nulambeh is a distinguished economist with a strong academic background 📚. He earned his PhD in International Economics from Bursa Uludag University, Turkey, in September 2020 🎓. Prior to that, he completed his Master of Science in Economics at the International Islamic University of Malaysia in January 2015 🌍. His academic journey began with a Bachelor of Science in Economics from the University of Yaoundé 2, Soa, Cameroon, in October 2009 📈. With expertise in economic research and analysis, Dr. Ndzembanteh continues to contribute to the field with valuable insights and global perspectives 🌎.

Award Achievements

Dr. Ndzembanteh Aboubakary Nulambeh is dedicated to providing quality education to undergraduate students 🎓. He meticulously prepares lesson plans and lecture notes 📚 to ensure a structured and engaging learning experience. Additionally, he designs tutorial worksheets and exam papers ✍️ to assess students’ understanding effectively. Beyond teaching, he takes on essential administrative tasks 🏢, contributing to curriculum development to enhance academic programs. His commitment to academic excellence fosters a productive learning environment, equipping students with the necessary knowledge and skills for success. Through his efforts, he plays a vital role in shaping future professionals in his field 🌟.

Conferences And Seminars

Dr. Ndzembanteh Aboubakary Nulambeh has made significant contributions to economic and environmental research. His study, The Role of Financial Development, Education, and Economic Growth on Environmental Quality in Cameroon (Istanbul Finance Conference, 2020), explores how financial progress and education influence environmental sustainability 🌱📈. Another key work, An Empirical Analysis of the Environmental Kuznets Curve: The Case of Cameroon (Uludağ University, 2019), examines the relationship between economic growth and environmental degradation 📊🌍. Additionally, his research on The Impact of Human Capital and Innovation Output on Economic Growth compares Malaysia and Turkey, highlighting the role of knowledge and creativity in economic progress 💡🚀.

Teaching and Mentorship

Dr. Ndzembanteh Aboubakary Nulambeh has a wealth of teaching experience across various institutions, including the Higher Institute of Management Studies, ISTGAC Maaron University Institute, and UNITAR International University. 📚 He has taught a range of subjects such as macro and microeconomics, statistics, mathematical economics, and sustainable finance, inspiring students in the field of economics. 💡 His dedication to education extends beyond teaching, as he actively guides students in research, fostering the next generation of economists. 🧑‍🎓 Additionally, his contributions to curriculum development highlight his commitment to enhancing academic programs in economics.

Research Focus

Dr. Ndzembanteh Aboubakary Nulambeh’s research focuses on the energy-environment nexus, economic growth, and development in sub-Saharan Africa. His studies address environmental economics, energy policy, financial development, trade openness, and foreign direct investment. He explores how these factors influence economic growth, environmental quality, and human capital. His work also examines the role of institutions in fostering sustainable development, innovation, and agricultural sector financing. 🌍📊💡📚💼🔋🌱

Publication Top Notes

Could industrialization and renewable energy enhance environmental sustainability: An empirical analysis for Sub-Saharan Africa?

Modeling the role of institutions on poverty and environmental sustainability: a panel analysis for British and French ex-colonies in Africa

Exploring the energy-environment growth nexus in francophone Africa in presence of institutions

The Role of Renewable Energy and Ecological Footprint on Economic Growth in Francophone African Countries in presence of Institutions

An Empirical Analysis of the Environmental Kuznets Curve: The Case of Cameroon

THE ROLE OF FINANCIAL DEVELOPMENT, EDUCATION AND ECONOMIC GROWTH ON ENVIRONMENTAL QUALITY IN CAMEROON

The role of financial development, human capital, and economic growth on environmental sustainability: an empirical analysis of Cameroon